Breaking Finance News

Zacks Investment Research downgraded Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to Sell in a report released today.

Yesterday Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) traded 1.54% higher at $1.34. The company’s 50-day moving average is $1.35 and its 200-day moving average is $1.18. The last closing price is up 11.90% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 589,097 shares of the stock were exchanged, down from an average trading volume of 597,874

Zacks Investment Research has downgraded Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) to Sell in a report released on 10/11/2016.

Previously on 10/4/2016, Zacks Investment Research reported on Cascadian Therapeutics Inc (USA) (NASDAQ:CASC) raised the target price from $0.00 to $2.00. At the time, this indicated a possible upside of 0.19%.

See Chart Below

Cascadian Therapeutics Inc (USA) (NASDAQ:CASC)

Cascadian Therapeutics Inc (USA) has a with a one year low of $0.82 and a one year high of $3.75 Cascadian Therapeutics Inc (USA)’s market capitalization is presently $0.

General Company Details For Cascadian Therapeutics Inc (USA) (NASDAQ:CASC)

Cascadian Therapeutics, Inc., formerly Oncothyreon Inc., is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapeutic products for the treatment of cancer. The Company's clinical-stage product candidate includes ONT-380, an orally active and selective small-molecule human epidermal growth factor receptor (HER) 2 inhibitor. The Company's ONT-10 is a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The Company is engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 (Chk1) kinase inhibitor and protocell technology. The Company completed the evaluation of approximately two dosing cohorts in its Phase Ib trial of ONT-10 in combination with the anti-CD27 T-cell agonist antibody varlilumab in collaboration with other company. The Company has completed Phase I trial of ONT-380, with both dose-escalation and expansion components. The Company has initiated Phase Ib trials of ONT-380.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.